CorMedix Inc. to Present at the Cantor Global Healthcare Conference
Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company, has announced its participation in the 2024 Cantor Global Healthcare Conference in New York, NY from September 17-19, 2024. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 10:55 AM EDT, along with one-on-one investor meetings.
The event provides an opportunity for CorMedix to showcase its focus on developing and commercializing therapeutic products for preventing and treating life-threatening conditions and diseases. Investors and interested parties can access a live webcast of the fireside chat through a provided link, with a replay available later on the company's website under the 'Events and Presentations' section.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CRMD gained 1.31%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024.
Cantor Global Healthcare Conference
| Date: | Thursday, September 19, 2024 | |
| Time: | 10:55AM EDT | |
| Format: | Fireside Chat and 1x1 Meetings | |
| Webcast: | Click Link | |
A replay of the fireside chat will also be available in the “Events and Presentations” page on the investor relations portion of the Company’s website at: www.cormedix.com
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When is CorMedix (CRMD) presenting at the Cantor Global Healthcare Conference?
What type of presentation will CorMedix (CRMD) give at the Cantor conference?
Where can investors watch CorMedix's (CRMD) presentation at the Cantor conference?
What is the focus of CorMedix (CRMD) as a biopharmaceutical company?
